linjc16/ctgov huggingface dataset:
Copeptin as a Stress Marker During a Written Examination

Study Overview
=================
Brief Summary
-----------------
To investigate whether copeptin levels increase upon a psychological stress (i.e. written examination) and whether copeptin levels measured immediately before the written examination predict success of the examination.

Official Title
-----------------
Copeptin as a Stress Marker During a Written Examination - the CoEXAM

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years Member of 4th year in medical course at Basel University Exclusion Criteria: Intake of any medication (except birth control pill) BMI over 30kg/m2 Evidence of acute disease History of chronic illness, including chronic psychiatric disease Anamnestic certain or assumed pregnancy Regularly smoking students

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in copeptin levels upon examination stress comparing copeptin levels prior and after examination |  | 4 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between copeptin levels prior to an exam and exam success |  | 4 hours | 
| Correlation to cortisol as the classical stress marker |  | 4 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
medical students, Basel University
Transcriptomic Profiling in Severely Injured Patients

Study Overview
=================
Brief Summary
-----------------
Discovery of differences in the host response in patients with systemic inflammation and sepsis, and identification of novel, specific markers by using a longitudinal clinico-transcriptomic approach.

Detailed Description
-----------------
The aim of this study is to link defined clinical phenotypes with data on RNA obtained from blood samples by high throughput technologies. Genetic and molecular characteristics of the immune system after severe trauma will be crosslinked to clinical aspects of posttraumatic organ failure, with the goal of identifying typical molecular fingerprints. Patients with and without sepsis or organ failure will be compared with the goal to develop a diagnostic test designed to predict the clinical course following severe trauma. Criteria for study enrollment includes patient age ≥18 y, an Injury Severity Score (ISS) ≥ 17 points, and time from injury to admission < 6 h. Whole blood from trauma patients will be collected within the first 6 h after trauma (day 0) and on days 1, 2, 3, 5, 7, 10, 14, and 21.

Official Title
-----------------
Transcriptomic Profiling in Severely Injured Patients

Conditions
-----------------
Trauma, Sepsis, Inflammation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient age ≥18 y Injury Severity Score (ISS) ≥ 17 points time from injury to admission < 6 h. Exclusion Criteria: Moribund Patients with: PH < 7,1 or Lactate > 15 mmol/l or Base deficit > 15 mEq/l

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trauma patients<br>age ≥18 y ISS ≥ 17 points admission < 6 h. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic Inflammation and Sepsis |  | 21 days after trauma | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | 28 days after Trauma | 
| Nosocomial infections |  | 21 days after trauma | 
| SOFA score |  | 21 days after trauma | 
| Systemic inflammation score |  | 21 days after trauma | 
| Hospital length of stay |  | 28 days after trauma | 
| ICU length of stay |  | 28 days after trauma | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcriptome profiling
The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of proton pump inhibitor for the treatment of non-erosive reflux disease (NERD) in Chinese population. Studies from the western population have estimated a worldwide prevalence of gastro-oesophageal reflux disease from 10 to 20 %. Monthly symptoms of heartburn or acid regurgitation were found in 9.3% of subjects according to a population survey in Hong Kong. Most of these patients did not show evidence of erosive change during upper endoscopy. However, patients with NERD suffer from similar impairment of quality of life as patients with erosive oesophagitis and their symptoms are as severe as patients with erosive disease. Data on the use of proton pump inhibitor for the treatment of NERD in Chinese patients are scanty. Thus we want to perform a double-blind randomised placebo-controlled study to evaluate the efficacy of proton pump inhibitor for the treatment of NERD in Chinese population.

Official Title
-----------------
The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population

Conditions
-----------------
Gastroesophageal Reflux

Intervention / Treatment
-----------------
* Drug: Esomeprazole 20mg once daily


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ambulatory patients with age between 18 -80 years old, Patients with predominant symptoms of heartburn or acid regurgitation at least once weekly with no evidence of endoscopic pathology. Exclusion Criteria: Patients under 18 or over 80 years of age, Symptoms of gastrointestinal bleeding, Patients who had previous upper gastrointestinal surgery, Patients with concomitant serious medical diseases, Patients who had received H2-receptor antagonists or proton pump inhibitors in the past 4 weeks, Pregnant or lactating women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Esomeprazole 20mg once daily|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms assessment, quality of life. |  | 12 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance |  | 8 Weeks | 
| Adverse effects |  | 8 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-erosive reflux disease
IGF1 Generation Test

Study Overview
=================
Brief Summary
-----------------
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.

Official Title
-----------------
A Multicentre Study on the Capacity of the IGF-1 Stimulation Test to Predict the Growth Promoting Effect of Standard and High Doses of Genotonorm® in Prepubertal Children With Growth Hormone Deficiency.

Conditions
-----------------
Growth Hormone Deficiency

Intervention / Treatment
-----------------
* Procedure: Blood sample
* Procedure: Radiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged of more than 4 years. GHD defined as a peak GH level < 20 mUI/ml at two different pharmacological GH provocative tests including one done with two pharmacological agents and both performed within the year before the inclusion, according to the current recommendations of the French Health Authorities Exclusion Criteria: Previous treatment with GH Ongoing pharmacological treatment with steroids except if corresponding to substitutive therapy

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Blood sample|nan|
|Procedure: Radiography|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of height standard deviation score after 24 months of treatment according to the short term response of plasma IGF1 to Genotonorm. |  |  |
Understanding Performance: Enhancing Recovery as Surgeons

Study Overview
=================
Brief Summary
-----------------
Reliably achieving peak performance requires balancing the strain of the prior day with sufficient recovery to be ready for the next day. Surgery has a long standing tradition long hours of hard work often at the expense of adequate sleep. Decreased sleep and recovery has physiologic consequences which can be measured using biometric data. The goal of this study is to quantify surgeon performance and biometric data to understand how modifiable behaviors can maximize recovery and performance.

Detailed Description
-----------------
Participants will be asked to wear a biometric sensor for six months. The biometric sensor, namely, 'The Whoop strap' collects heart rate and heart rate variability data. Other data gathered will be in the form of surveys and comments from subjects on wellness, burnout, modifiable activities including sleep, nutrition, exercise and mindfulness, and surgical performance as well as video and audio recordings during a simulated surgical task. Surveys will be individually numbered and a master list of subject number and video, audio, and sensor ID will be kept in a separate location. This practice will enable us to better understand survey feedback by reviewing relevant videos, images, and sensor recordings. Images and data associated with a subject will be labeled with the subject number only.

Official Title
-----------------
Use of Biometric Data to Understand Surgeon Performance, Strain, and Recovery

Conditions
-----------------
Burnout, Professional

Intervention / Treatment
-----------------
* Device: Whoop


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study participants will include trainee and attending surgeons Exclusion Criteria: Exclusion criteria will be anyone who is not full-time clinically active as a surgical trainee or attending

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Whoop|Wear WHOOP Strap, complete surveys|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgeon Recovery | A daily Recovery score from 0-100% (0-33% is poor recovery, 34-66% is medium recovery, 67-100% is good recovery) is calculated using the WHOOP algorithm which takes resting heart rate, heart rate variability, and sleep metrics into account. | 6-12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Strain | Strain scores are calculated using the WHOOP algorithm which uses heart rate, activity, and duration of activity. The Clinical Strain will refer to the Strain calculated by the WHOOP strap that occurs during clinical activities including overnight call and operative cases. | 6-12 months |
Evaluation of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Primary Anterior Teeth

Study Overview
=================
Brief Summary
-----------------
This study aim to evaluate knowledge, attitude, and practice of intern dentistry in emergency management of traumatic dental injures in primary anterior teeth in children aged from 3-5 years old. Questionnaire survey will be designed to evaluate Knowledge - Attitude - and practice of intern dentists who met the eligibility criteria

Detailed Description
-----------------
Questionnaire survey will be designed to evaluate Knowledge - Attitude - and practice of intern dentists toward different forms of traumatic dental injuries in primary anterior teeth in children aged from 3 to 5 years old.

Official Title
-----------------
Evaluation of Knowledge- Attitude- Practice (KAP) of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Primary Anterior Teeth: A Cross-sectional Study

Conditions
-----------------
Traumatic Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intern dentists attending their internship in Faculty of Dentistry- Cairo University, other private university (Modern Science and Arts University- MSA). The intern dentists who agree to participate. Intern dentists who did not attend Pediatric Dentistry round, Endodontic round, Emergency round and Surgery round at Cairo University. Intern dentists irrespective of age and sex.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge, attitude and practice (KAP) of intern dentists | measured by Knowledge, attitude and practice Questionnaire and the measuring unit is Binary (yes, no) | 1 year | 
| Knowledge, attitude and practice (KAP) of intern dentists | measured by Knowledge, attitude and practice Questionnaire and the measuring unit is Multiple choice questions | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dental trauma, emergency management, traumatic injures.
Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination

Study Overview
=================
Brief Summary
-----------------
The aim of study is to describe the clinical, immunological, serological, virological and therapeutic characteristics of HIV+ patients harboring isolated anti-HBc profile and to assess the response to vaccination in these patients.

Official Title
-----------------
Study of Immunological, Virological, Serological Characteristics of HIV+ Patients Harboring Isolated Anti-HBc Profile and Response to Hepatitis B Vaccination

Conditions
-----------------
HIV Infection, Hepatitis B

Intervention / Treatment
-----------------
* Other: blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV+ adults patients negative HBsAg negative a-HBs Ab positive HBc Ab without HBV - vaccination CD4 cell above 200 /mm3 HIV viral load below 50 copies/mL Exclusion Criteria: positive HBs antigenemia in the past transaminitis above fivefold upper normal limit PT<50% or Platelet <50 000/mm3 ongoing opportunistic infection ongoing or recent systemic corticoid or immunomodulatory therapy, splenectomy, pregnancy, contra-indication to intramuscular injection, familial history of neurological disease.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| vaccination<br>Anti-HBV vaccine injection | Other: blood sampling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of immunological, virological and serological characteristics associated to anti-HBc isolated profile |  | at Day 0, inclusion visite | 
| Average titers of anti-HBs Ab |  | at 4 weeks, 28 weeks and 18 months after the first vaccination HBV | 
| Analysis of B-cell phenotype and maturation |  | at baseline and at week 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with HBsAb titers as protective titer>10 IU/L |  | at 4 weeks,28 weeks and 18 month after the first dose HBV vaccin | 
| Detection of IgG+ memory B cells specific for HBcAg or HBs Ag |  | at baseline and 28 weeks after the first dose HBV vaccin | 
| - Detection of HBV preS2 and S-specific T cells |  | at day 0 and week 28 |
Use of V-Loc Suture for Mid-face Lifting in Short-flap Rhytidectomy

Study Overview
=================
Brief Summary
-----------------
This study will evaluate and measure the Vloc suture's ability to elevate the mid-face when using a short flap, short incision technique in during a traditional face-lift. The objective of this study is to assess the suture's potential in elevating the mid-face when a traditional Lifestyle facelift is performed. We hypothesize that the Vloc suture will elevate the mid-face more effectively when using a short flap, short incision technique on a traditional facelift.

Detailed Description
-----------------
A total of 25 patients who are already receiving a traditional Lifestyle Lift will be asked to participate. Once the consent form has been signed by the patient, the facelift will be performed as scheduled and the Vloc suture will be added to the mid-face area. Each patient will be added to a database and their progress will be tracked with photos taken before, at 6 weeks, and at 6 months following the procedure. All data stored will be locked into a hard drive that can only be accessed by the research staff and the doctor. The text data will be used by research staff for reports and articles. * you must already have purchased and scheduled a facelift procedure with Lifestyle Lift to participate in this trial. The addition of only the V-loc suture is at no cost.

Official Title
-----------------
Use of the V-Loc Suture for Mid-Face Lifting in Short-flap Rhytidectomy

Conditions
-----------------
Use of the Vloc Suture, Elevation of the Mid-face

Intervention / Treatment
-----------------
* Device: V-Loc Suture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are scheduled to receive a Lifestyle Lift will be asked to participate. The first 25 patients who have consented will be included into the study. Exclusion Criteria: Any patient who is not able to receive a facelift for whatever reason, or who do not want a facelift will not be apart of this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rhytidectomy with Covidien<br>25 patients receiving a mid-face lift in short-flap rhytidectomy | Device: V-Loc Suture<br> <br> * Other names: Covidien;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Elevation of the mid-face |  | Initial- 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No Retention of Mid-face |  | initial-6 Months |
Novel Influenza A (H1N1) Surveillance Registry

Study Overview
=================
Brief Summary
-----------------
The demographic characteristics, clinical features, course, and outcomes of severe H1N1 influenza infection requiring intensive care have not been defined rigorously and systematically. While the majority of patients in early reports of critically ill novel influenza A (H1N1) have respiratory involvement, up to 10-20% may present with non-respiratory organ failures, such as shock, seizures, or acute renal failure. The burden of disease and resource utilization of these patients remains largely unknown. The purpose of this surveillance registry is to characterize the demographics, clinical features, outcomes, and resource utilization of patients with H1N1 influenza infection who require intensive care.

Official Title
-----------------
Novel Influenza A (H1N1) Surveillance Registry

Conditions
-----------------
H1N1, Novel Influenza A, Influenza

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admission to an intensive care unit at a participating site with confirmed or suspected Novel H1N1 Influenza infection Exclusion Criteria: Influenza-like illness due to non-influenza disease and negative testing for influenza
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adult H1N1<br>Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection | |
| Pediatric H1N1<br>Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |